British pharma major AstraZeneca, which in partnership with Oxford University developed one of the first and most popular COVID-19?vaccines?has admitted for the first time that it has caused a rare side effect in some recipients. In a court filing in the UK, AstraZeneca has accepted that its COVID vaccine?¡°can, in?very rare?cases, cause TTS¡±.?
TTS (Thrombosis with Thrombocytopenia Syndrome) causes blood clots and a low blood platelet count in humans.?TTS can be caused by bone?marrow?disorders or an immune system problem.?It can be a side effect of taking certain medications.?TTS can affect both children and adults.
The admission was made by AstraZeneca at the High Court in?February,?in a class action lawsuit over claims its vaccine caused death and serious injury in 51 cases.
"It is admitted that the AZ vaccine can, in?very rare?cases, cause TTS. The causal mechanism is not known...Further, TTS can also occur?in the absence of?the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,"?AstraZeneca said.
AstraZeneca is being sued for over ?100 million (a little over Rs 1,000 crore) by those who suffered health complications, allegedly after receiving the COVID-19 vaccine shots.
According to one of the complainants, Jamie Scott, he had received the vaccine in April 2021?which?caused him a permanent brain injury after a blood clot.?This?has prevented him from working?and?the hospital even told his wife thrice that?he's?going to die.
In the past?AstraZeneca?had?denied any links between its vaccines and TTS.
In India, the Oxford¨CAstraZeneca COVID-19 vaccine was produced and marketed by Pune-based Serum Institute of India (SII) as Covishield.?It was also sold?under the brand name Vaxzevria in some parts of the globe.
According to?reports?as many as 1,749,417,978 doses of the Covishield vaccine have?been administered?in India.?
For more news and current affairs?from around the world, please visit?Indiatimes News.